Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Aged 3-5 years~* Diagnosis of cystic fibrosis~Exclusion Criteria:~* Children taking scheduled inhaled Pulmozyme or hypertonic saline within 56 days prior to Visit 1 or any Pulmozyme in the 28 days before Visit 1~* Involvement in a clinical intervention trial within the 4 weeks prior to Visit 1~* Use of an investigational drug or device within 28 days prior to Visit 1~* Any other condition that might increase the risk of participation to the patient in the judgement of the investigator

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Dornase alfa (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).